Gastroesophageal Reflux Disease (GERD) Market Size, Share, Trends, Growth Outlook

Gastroesophageal Reflux Disease (GERD) Market is estimated to increase at a growth rate of 4.1% CAGR over the forecast period from 2024 to 2030.

The global Gastroesophageal Reflux Disease (GERD) Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Diagnosis (Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry, Others), By Drug (Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, Others).

An Introduction to Gastroesophageal Reflux Disease (GERD) Market in 2024

The Gastroesophageal Reflux Disease (GERD) Market comprises pharmaceuticals, medical devices, and treatment modalities aimed at managing gastroesophageal reflux disease, a common digestive disorder characterized by chronic acid reflux and heartburn. This market includes proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, lifestyle modifications, and minimally invasive procedures such as endoscopic therapies and surgical interventions to alleviate GERD symptoms, reduce esophageal damage, and improve patients' quality of life.

Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape

The global Gastroesophageal Reflux Disease (GERD) Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Gastroesophageal Reflux Disease (GERD) Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Gastroesophageal Reflux Disease (GERD) Industry include- AstraZeneca Plc, Aurobindo Pharma, Glenmark, Haleon Group of Companies , Johnson & Johnson, Medtronic Plc, Pfizer Inc, Reckitt Benckiser Group PLC, SRS Life Sciences, Takeda Pharmaceutical Co. Ltd, Teva Pharmaceuticals Industries Ltd, TWi Pharmaceuticals Inc, Zydus Group.

Gastroesophageal Reflux Disease (GERD) Market Trend: Rise in Minimally Invasive Treatment Options

A significant trend in the market for gastroesophageal reflux disease (GERD) is the increasing adoption of minimally invasive treatment options for managing the condition. Minimally invasive procedures such as laparoscopic fundoplication and transoral incisionless fundoplication (TIF) offer effective alternatives to traditional open surgery for treating GERD, providing patients with reduced postoperative discomfort, shorter recovery times, and fewer complications. This trend reflects the growing preference among patients and healthcare providers for less invasive treatment modalities that offer comparable efficacy to surgical interventions, driving market growth and innovation in minimally invasive GERD treatments.

Gastroesophageal Reflux Disease (GERD) Market Driver: Growing Prevalence of GERD and Associated Complications

A key driver in the GERD market is the growing prevalence of GERD and its associated complications, such as Barrett's esophagus, esophageal strictures, and erosive esophagitis. GERD is a common chronic condition characterized by the reflux of stomach acid into the esophagus, leading to symptoms such as heartburn, regurgitation, and chest pain. As the incidence of GERD continues to rise due to factors such as obesity, poor dietary habits, and lifestyle changes, there is an increasing demand for effective treatment options to alleviate symptoms, prevent disease progression, and improve quality of life for patients with GERD. This driver underscores the importance of developing innovative therapies and treatment strategies to address the growing burden of GERD and its complications, driving market demand for GERD treatments.

Gastroesophageal Reflux Disease (GERD) Market Opportunity: Development of Novel Pharmacological Therapies

One Market Opportunity in the GERD market lies in the development of novel pharmacological therapies that target specific mechanisms underlying GERD pathophysiology. There is a need for new pharmacological agents that provide effective symptom relief, promote esophageal healing, and address underlying factors contributing to GERD, such as impaired esophageal motility or dysfunction of the lower esophageal sphincter. Additionally, the development of combination therapies that target multiple aspects of GERD pathogenesis, such as acid suppression, mucosal protection, and esophageal motility, presents opportunities to improve treatment efficacy and patient outcomes. This opportunity enables pharmaceutical companies and researchers to innovate in the development of next-generation GERD treatments, address unmet medical needs, and capitalize on the growing market demand for effective pharmacological interventions for GERD management.

Gastroesophageal Reflux Disease Market Share Analysis: Proton Pump Inhibitors (PPIs) is the fastest growing market segment over the forecast period to 2030

Proton Pump Inhibitors (PPIs) stand out as the fastest-growing segment in the treatment landscape for gastroesophageal reflux disease (GERD), owing to their widespread use and efficacy in symptom management. PPIs work by blocking the proton pump in the stomach lining, thereby reducing the production of stomach acid and alleviating symptoms such as heartburn, regurgitation, and chest pain associated with GERD. With the prevalence of GERD on the rise globally, driven by factors such as dietary habits, obesity, and lifestyle changes, there's a growing demand for effective pharmacological interventions to manage the condition. PPIs have become the cornerstone of GERD treatment due to their rapid onset of action, high efficacy rates, and relatively low incidence of adverse effects. Moreover, advancements in PPI formulations, including extended-release formulations and combination therapies, have further enhanced their efficacy and patient compliance. As healthcare providers increasingly recognize the significance of adequate acid suppression in the management of GERD and its associated complications, the demand for PPIs is expected to continue its rapid growth trajectory, positioning them as a key therapeutic option in the management of GERD.

Gastroesophageal Reflux Disease (GERD) Market Segmentation

By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Gastroesophageal Reflux Disease (GERD) Companies

AstraZeneca Plc
Aurobindo Pharma
Glenmark
Haleon Group of Companies
Johnson & Johnson
Medtronic Plc
Pfizer Inc
Reckitt Benckiser Group PLC
SRS Life Sciences
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceuticals Industries Ltd
TWi Pharmaceuticals Inc
Zydus Group
* List not Exhaustive

Reasons to Buy the Gastroesophageal Reflux Disease (GERD) Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Gastroesophageal Reflux Disease (GERD) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Gastroesophageal Reflux Disease (GERD) Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Gastroesophageal Reflux Disease (GERD) Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Gastroesophageal Reflux Disease (GERD) Market Size Outlook, $ Million, 2021 to 2030
3.2 Gastroesophageal Reflux Disease (GERD) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Gastroesophageal Reflux Disease (GERD) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Gastroesophageal Reflux Disease (GERD) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Gastroesophageal Reflux Disease (GERD) Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Gastroesophageal Reflux Disease (GERD) Industry
4.2 Key Market Trends in Gastroesophageal Reflux Disease (GERD) Industry
4.3 Potential Opportunities in Gastroesophageal Reflux Disease (GERD) Industry
4.4 Key Challenges in Gastroesophageal Reflux Disease (GERD) Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Gastroesophageal Reflux Disease (GERD) Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Gastroesophageal Reflux Disease (GERD) Market Outlook by Segments
7.1 Gastroesophageal Reflux Disease (GERD) Market Outlook by Segments, $ Million, 2021- 2030
By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
8 North America Gastroesophageal Reflux Disease (GERD) Market Analysis and Outlook To 2030
8.1 Introduction to North America Gastroesophageal Reflux Disease (GERD) Markets in 2024
8.2 North America Gastroesophageal Reflux Disease (GERD) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Gastroesophageal Reflux Disease (GERD) Market size Outlook by Segments, 2021-2030
By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
9 Europe Gastroesophageal Reflux Disease (GERD) Market Analysis and Outlook To 2030
9.1 Introduction to Europe Gastroesophageal Reflux Disease (GERD) Markets in 2024
9.2 Europe Gastroesophageal Reflux Disease (GERD) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Gastroesophageal Reflux Disease (GERD) Market Size Outlook by Segments, 2021-2030
By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
10 Asia Pacific Gastroesophageal Reflux Disease (GERD) Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Gastroesophageal Reflux Disease (GERD) Markets in 2024
10.2 Asia Pacific Gastroesophageal Reflux Disease (GERD) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Gastroesophageal Reflux Disease (GERD) Market size Outlook by Segments, 2021-2030
By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
11 South America Gastroesophageal Reflux Disease (GERD) Market Analysis and Outlook To 2030
11.1 Introduction to South America Gastroesophageal Reflux Disease (GERD) Markets in 2024
11.2 South America Gastroesophageal Reflux Disease (GERD) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Gastroesophageal Reflux Disease (GERD) Market size Outlook by Segments, 2021-2030
By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
12 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Gastroesophageal Reflux Disease (GERD) Markets in 2024
12.2 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Market size Outlook by Segments, 2021-2030
By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca Plc
Aurobindo Pharma
Glenmark
Haleon Group of Companies
Johnson & Johnson
Medtronic Plc
Pfizer Inc
Reckitt Benckiser Group PLC
SRS Life Sciences
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceuticals Industries Ltd
TWi Pharmaceuticals Inc
Zydus Group
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Diagnosis
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Others
By Drug
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Others